Adjuvant Long-Acting Muscarinic Antagonist Improves Asthma

Share this content:
Adjuvant Long-Acting Muscarinic Antagonist Improves Asthma
Adjuvant Long-Acting Muscarinic Antagonist Improves Asthma

WEDNESDAY, March 21, 2018 (HealthDay News) -- For patients with persistent asthma, the use of long-acting muscarinic antagonists (LAMAs) versus placebo as an adjunct to inhaled corticosteroids, and combined use of inhaled corticosteroids and long-acting β-agonists (LABAs), termed single maintenance and reliever therapy (SMART), are associated with a reduced risk of exacerbations, according to two reviews published online March 19 in the Journal of the American Medical Association.

Diana M. Sobieraj, Pharm.D., from the University of Connecticut School of Pharmacy in Storrs, and colleagues reviewed the effects associated with LAMA versus placebo versus another controller as an adjunct to inhaled corticosteroids in patients with uncontrolled persistent asthma. Data were included from 15 randomized clinical trials with 7,122 patients. The researchers found that the risk of exacerbations requiring systemic corticosteroids was significantly reduced by adding LAMA versus placebo to inhaled corticosteroids (risk ratio, 0.67); there was no significant improvement in the exacerbation risk for adding LAMA versus LABA.

In a second study, Sobieraj and colleagues conducted a review of the effects of SMART in patients with persistent asthma. Data were reviewed from 16 randomized clinical trials with 22,748 patients. The researchers found that SMART correlated with a reduced risk of asthma exacerbations compared with the same or a higher dose of inhaled corticosteroids and LABA as the controller therapy (relative risks, 0.68 and 0.77, respectively).

"The use of single maintenance and reliever therapy compared with inhaled corticosteroids as the controller therapy (with or without a long-acting β-agonist) and short-acting β-agonists as the relief therapy was associated with a lower risk of asthma exacerbations," Sobieraj and colleagues write in the second study.

Abstract/Full Text 1
Abstract/Full Text 2
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »